# A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

> **NCT01617187** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 360 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Asenapine
- **DRUG:** Placebo Asenapine
- **DRUG:** Olanzapine
- **DRUG:** Placebo Olanzapine

## Key facts

- **NCT ID:** NCT01617187
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-04
- **Primary completion:** 2014-08-11
- **Final completion:** 2014-09-09
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617187, "A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01617187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*